scope by the use of historical controls. Prospective studies with greater numbers of patients are necessary to determine the survival benefit and potential cost effectiveness of this technology.
Background: Reference intervals are regularly included with laboratory test results in order to provide a context for test results. As access to transgender healthcare becomes more available in the United States, interpreting laboratory results is difficult within the male/female gender binary reference intervals. Previous research studied interpretation of laboratory results in transgender women (transfemales), identifying significant differences in transfemale hematocrit, hemoglobin, creatinine, LDL cholesterol, and triglycerides compared to healthy cisgender controls. This study did not address the reference interval issue. Little to no literature exists investigating the impact of hormone therapy (HT) on reference intervals in laboratory testing of transgender individuals. Objectives: The goal of this study was to review laboratory test results for transgender patients receiving care at our institution to investigate how HT impacts commonly ordered laboratory test and the respective reference intervals. Methods: In this retrospective study at an academic medical center, electronic health records were searched to identify transgender patients seen at our institution in the time period of January 1, 2012, to May 1, 2016. Patients for analysis were verified as transgender by chart review, were at least 18 years old, had laboratory testing during the period of study, and were receiving either estrogen or testosterone as HT as a component of gender-affirming treatment for at least six months. Results: Verified transgender patients were separated into a transgender men (transmale) cohort (n = 120) and a transfemale cohort (n = 119). For comparison, we identified patients who had lab testing done prior to initiation of HT for use as a baseline measurement, then had testing performed again after at least six months of HT. In the transfemale cohort, we identified individuals with lab results before and after initiating HT for creatinine (n = 42), hemoglobin (n = 11), hematocrit (n = 11), LDL cholesterol (n = 22), and triglycerides (n = 11). There was a statistically significant difference (P < .05) in the hematocrit levels of transfemales after initiating HT. In the transmales, we identified individuals with lab results before and after initiating HT for creatinine (n = 10), hemoglobin (n = 21), hematocrit (n = 19), LDL cholesterol (n = 10), and triglycerides (n = 6). There was a statistically significant difference (P < .05) in the triglycerides levels of the transmale cohort after initiating HT, and a more powerful statistically significant difference (P < .005) in the creatinine, hemoglobin, and hematocrit levels of the transmale cohort after initiating HT. Data obtained during the study has shown to be complex; analysis is ongoing. Conclusions: Our study is the largest effort to date to analyze the effect of HT on laboratory testing patterns in transgender individuals. Preliminary data suggest significant changes to laboratory test values in both cohorts after initiation of HT. Further analysis is necessary. In mechanical circulatory support (MCS) patients, proper heparin dosing is critical to avoid circuit thrombosis and bleeding complications; however, PTT and anti-Xa activity tests used for heparin monitoring may be discordant. In order to better characterize this discordance, we describe data from adult MCS patients for six months of paired PTT/anti-Xa activity and eight months of PTT/anti-Xa activity with concurrent laboratory results for PT, antithrombin antigen (ATAg), factor VIII (F8), and C-reactive protein (CRP). At our institution, the therapeutic range for unfractionated heparin is 0.30-0.70 IU/mL for anti-Xa activity and 60-100 seconds for PTT. Concordance between PTT and anti-Xa activity is defined as PTT<60 seconds and anti-Xa <0.3 IU/mL, PTT 60-100 seconds and anti-Xa activity 0.3-0.7 IU/mL, or PTT>100 seconds and anti-Xa activity >0.7 IU/mL. A retrospective review of adult MCS patients from May 1, 2016 to October 19, 2016 representing 2,078 paired PTT/anti-Xa measurements from 96 patients revealed only 593 (28.5%) were concordant. Of the remaining 1485 discordant pairs, 16 had anti-Xa activity results greater than expected for the paired PTT, and 1,469 (98.9%) had PTT results greater than expected for the paired anti-Xa activity. From June 1, 2016 to January 31, 2017, clinicians concerned about discordant PTT/anti-Xa activity ordered a battery of tests, including a 1:1 mixing study of PT, PTT, thrombin time (TT) with heparinase treatment, ATAg, F8 activity, and CRP. For 104 samples from 71 patients, only 12 demonstrated concordance, while 92 showed discordance-all with higher than expected PTT values. The panel was preferentially ordered for supratherapeutic PTT >100 seconds (69/92), and none of the
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